AR025307A1 - Compuesto de liberacion sostenida de un peptido, microparticulas, composicion farmaceutica y el uso de dicho compuesto para la fabricacion de un medicamento - Google Patents
Compuesto de liberacion sostenida de un peptido, microparticulas, composicion farmaceutica y el uso de dicho compuesto para la fabricacion de un medicamentoInfo
- Publication number
- AR025307A1 AR025307A1 ARP000104253A ARP000104253A AR025307A1 AR 025307 A1 AR025307 A1 AR 025307A1 AR P000104253 A ARP000104253 A AR P000104253A AR P000104253 A ARP000104253 A AR P000104253A AR 025307 A1 AR025307 A1 AR 025307A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- sustained release
- pharmaceutical composition
- microparticles
- peptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Se refiere a un complejo de liberacion sostenida, el compuesto 1 que comprende el Compuesto (A) que tiene la formula 1 o una sal farmacéuticamenteaceptable del mismo y un copolímero que comprende ácido poli-(I)láctico-glicolico-tartárico (P(I)LGT), donde el grupo amino de dicho compuesto (A)estáionicamente unido a un grupo carboxilo de I P(I)LGT. Se refiere asimismo a un proceso para preparar dicho complejo de liberacion sostenida. Más aun, lapresente invencion se refiere a una composicion farmacéutica que comprende dicho complejo de liberacion sostenida y uno o más vehículos farmacéuticamenteaceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14964999P | 1999-08-18 | 1999-08-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR025307A1 true AR025307A1 (es) | 2002-11-20 |
Family
ID=22531239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000104253A AR025307A1 (es) | 1999-08-18 | 2000-08-17 | Compuesto de liberacion sostenida de un peptido, microparticulas, composicion farmaceutica y el uso de dicho compuesto para la fabricacion de un medicamento |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1204429B1 (es) |
JP (2) | JP4303438B2 (es) |
KR (1) | KR20020031407A (es) |
CN (1) | CN1164334C (es) |
AR (1) | AR025307A1 (es) |
AT (2) | ATE252915T1 (es) |
AU (1) | AU767837B2 (es) |
CA (1) | CA2391333C (es) |
CZ (1) | CZ2002333A3 (es) |
DE (2) | DE60027334T2 (es) |
DK (1) | DK1204429T3 (es) |
ES (2) | ES2209948T3 (es) |
HK (1) | HK1043308B (es) |
HU (1) | HUP0203060A3 (es) |
IL (1) | IL147802A0 (es) |
MX (1) | MXPA02001699A (es) |
NO (1) | NO20020771L (es) |
NZ (2) | NZ526127A (es) |
PL (1) | PL354120A1 (es) |
PT (1) | PT1204429E (es) |
RU (1) | RU2237675C2 (es) |
WO (1) | WO2001012233A2 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004200688B2 (en) * | 1999-08-18 | 2007-01-25 | Ipsen Pharma S.A.S. | Sustained release formulation of a peptide |
IES990700A2 (en) * | 1999-08-18 | 2001-08-22 | Kinerton Ltd | Process to make a sustained release formulation |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EP1594517B1 (en) | 2003-01-28 | 2007-06-20 | Microbia, Inc. | Compositions for the treatment of gastrointestinal disorders |
PT1682537E (pt) | 2003-11-05 | 2012-06-20 | Sarcode Bioscience Inc | Moduladores de adesão celular |
MY158342A (en) | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
DK1881823T3 (en) | 2005-05-17 | 2015-03-02 | Sarcode Bioscience Inc | COMPOSITION AND PROCEDURES FOR TREATMENT OF EYE DISORDERS |
WO2007145956A2 (en) * | 2006-06-05 | 2007-12-21 | Novartis Ag | USE OF TGF-β ANTAGONISTS IN TREATMENT OF PARATHYROID-RELATED DISORDERS |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
ES2830024T3 (es) | 2007-10-19 | 2021-06-02 | Novartis Ag | Composiciones y métodos para el tratamiento del edema macular |
US8080562B2 (en) | 2008-04-15 | 2011-12-20 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
EP3239170B1 (en) | 2008-06-04 | 2019-03-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2011050175A1 (en) | 2009-10-21 | 2011-04-28 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
AU2012250776B2 (en) | 2011-05-04 | 2017-06-15 | Balance Therapeutics, Inc. | Pentylenetetrazole derivatives |
CN110922393A (zh) | 2012-07-25 | 2020-03-27 | 诺华股份有限公司 | Lfa-1抑制剂及其多晶型物 |
US9545446B2 (en) | 2013-02-25 | 2017-01-17 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
EP3054969B1 (en) | 2013-10-10 | 2021-03-10 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions |
AR101476A1 (es) | 2014-08-07 | 2016-12-21 | Acerta Pharma Bv | Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk) |
JP2019506383A (ja) | 2016-01-11 | 2019-03-07 | シナジー ファーマシューティカルズ インコーポレイテッド | 潰瘍性大腸炎を治療するための製剤および方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6221958B1 (en) * | 1993-01-06 | 2001-04-24 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
WO1994015587A2 (en) * | 1993-01-06 | 1994-07-21 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
SI9420051A (en) * | 1993-08-09 | 1996-12-31 | Biomeasure Inc | Chemical modified peptide derivatives, process for their preparation and their use in human therapy |
IL126422A (en) * | 1996-04-23 | 2004-02-19 | Kinerton Ltd | Biodegradable acidic polylactic polymers and methods for their preparation |
IE960308A1 (en) * | 1996-04-23 | 1997-11-05 | Kinerton Ltd | Sustained release ionic conjugate |
AR020650A1 (es) * | 1998-08-10 | 2002-05-22 | Poly Med Inc | Polimeros fosforilados y conjugados de los mismos |
IES990700A2 (en) * | 1999-08-18 | 2001-08-22 | Kinerton Ltd | Process to make a sustained release formulation |
-
2000
- 2000-08-16 AT AT00954105T patent/ATE252915T1/de not_active IP Right Cessation
- 2000-08-16 ES ES00954105T patent/ES2209948T3/es not_active Expired - Lifetime
- 2000-08-16 AT AT03076829T patent/ATE322911T1/de not_active IP Right Cessation
- 2000-08-16 JP JP2001516576A patent/JP4303438B2/ja not_active Expired - Fee Related
- 2000-08-16 DE DE60027334T patent/DE60027334T2/de not_active Expired - Lifetime
- 2000-08-16 ES ES03076829T patent/ES2258204T3/es not_active Expired - Lifetime
- 2000-08-16 PT PT00954105T patent/PT1204429E/pt unknown
- 2000-08-16 DE DE60006250T patent/DE60006250T2/de not_active Expired - Lifetime
- 2000-08-16 RU RU2002106820A patent/RU2237675C2/ru not_active IP Right Cessation
- 2000-08-16 AU AU66444/00A patent/AU767837B2/en not_active Ceased
- 2000-08-16 HU HU0203060A patent/HUP0203060A3/hu unknown
- 2000-08-16 WO PCT/US2000/022464 patent/WO2001012233A2/en not_active Application Discontinuation
- 2000-08-16 MX MXPA02001699A patent/MXPA02001699A/es active IP Right Grant
- 2000-08-16 CZ CZ2002333A patent/CZ2002333A3/cs unknown
- 2000-08-16 EP EP00954105A patent/EP1204429B1/en not_active Expired - Lifetime
- 2000-08-16 DK DK00954105T patent/DK1204429T3/da active
- 2000-08-16 CA CA002391333A patent/CA2391333C/en not_active Expired - Fee Related
- 2000-08-16 NZ NZ526127A patent/NZ526127A/en unknown
- 2000-08-16 NZ NZ517646A patent/NZ517646A/en unknown
- 2000-08-16 IL IL14780200A patent/IL147802A0/xx unknown
- 2000-08-16 CN CNB008114943A patent/CN1164334C/zh not_active Expired - Fee Related
- 2000-08-16 PL PL00354120A patent/PL354120A1/xx not_active Application Discontinuation
- 2000-08-16 KR KR1020027001919A patent/KR20020031407A/ko not_active Application Discontinuation
- 2000-08-17 AR ARP000104253A patent/AR025307A1/es unknown
-
2002
- 2002-02-15 NO NO20020771A patent/NO20020771L/no unknown
- 2002-06-25 HK HK02104716.3A patent/HK1043308B/zh not_active IP Right Cessation
-
2005
- 2005-08-22 JP JP2005239282A patent/JP2006008701A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR025307A1 (es) | Compuesto de liberacion sostenida de un peptido, microparticulas, composicion farmaceutica y el uso de dicho compuesto para la fabricacion de un medicamento | |
NO20006282D0 (no) | Nye cyklosporiner | |
AR035927A1 (es) | Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr | |
CO5280060A1 (es) | Aminoacidos biciclicos como agentes farmaceuticos | |
EA200200571A1 (ru) | Новая композиция и ее применение | |
NL300281I2 (nl) | Exenatide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
BRPI0015567B8 (pt) | composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica | |
WO2005028516A3 (en) | Albumin-binding derivatives of therapeutic peptides | |
BR0115965A (pt) | Composições farmacêuticas para a liberação oral de agentes farmacologicamente ativos | |
CO5280073A1 (es) | Composiciones | |
ID21956A (id) | Asam n-(aril dan atau heteroarilasetil) amino ester, komposisi farmasi yang mengandungnya, dan metoda untuk menghambat pelepasan betha-amiloid peptida dan atau sintesanya dengan menggunakan senyawa tersebut | |
CO5640149A2 (es) | Formulaciones parenterales de un peptido para el tratamiento de lupus sistematico eritematoso | |
BR0207872A (pt) | Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração | |
BR0214199A (pt) | Composições de fenóxi amina para liberar agentes ativos, forma de unidade de dosagem e método de administração | |
UY27548A1 (es) | Sales de ácido succínico de 5,7,14-triazatetraciclo (10.3.1.02.11.04,9) exadeca-2 (11),3,5,7,9-pentaeno y composiciones farmacéuticas | |
BR0212787A (pt) | Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica | |
CO5070569A1 (es) | Compuesto de aminoazol o una sal farmaceuticamente aceptable del mismo y medicamento que los contienen | |
BR0111868A (pt) | Composições farmacêuticas | |
ATE259795T1 (de) | Carbonsäuren und acylsulfonamide, solche verbindungen enthaltende zubereitungen und behandlungsmethoden | |
EA200401108A1 (ru) | Соли толтеродина | |
SE0102440D0 (sv) | New compound | |
PT1079849E (pt) | Utilizacao de proteinas hmg para a preparacao de medicamentos com actividade citotoxica | |
NO20023551D0 (no) | Ibuprofen-inneholdende aktivt middel-preparat | |
ATE455761T1 (de) | Neue atorvastatinsalze und pharmazeutische zusammensetzungen, die diese enthalten | |
DE60024648D1 (de) | Carbonsäuren und acylsulfonamide, diese verbindungen enthaltende zubereitungen und behandlungsmethoden |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |